Investigating Therapeutic Potential of Beta‐Glucan on Experimental Toxoplasmosis in Immunocompetent and Immunocompromised Mice: In Silico and in Vivo Studies
Chemistry & Biodiversity · 2025
DOI: 10.1002/cbdv.202500370 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chemistry & Biodiversity, 2025. Verfasst von Asmaa A Aboul-Fotouh und 4 weiteren Autor:innen. Beteiligte Einrichtung: Zoology Department, Faculty of Science for Girls, Al-Azhar University, Cairo, Egypt. Hauptthemen laut MEDLINE: beta-Glucans, Toxoplasmosis, Antiprotozoal Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 65 Literaturangaben.
Abstract (Originalsprache)
There is a need to find efficient treatment for toxoplasmosis, a global disease with a public health concern, as the used therapeutics have limited effectiveness. Beta‐glucan (β‐glucan), a natural polysaccharide, has anti‐inflammatory, immunomodulatory, and anti‐infective activities against bacteria, viruses, and parasites. We aimed to investigate the therapeutic efficacy of β‐glucan on toxoplasmosis using an in silico study and an in vivo mice model. The β‐glucan drug‐likeness characteristics were evaluated by molecular docking simulations, Lipinski's RO5 filter analysis, and the computational quantitative structural‐activity relationships/absorption, distribution, metabolism, excretion, and toxicity predictive characteristics compared to spiramycin, an anti‐toxoplasmosis drug. Sixty albino mice were divided into two divisions, immunocompetent and immunosuppressed. Each division contained five groups; healthy, diseased, spiramycin‐treated, β‐glucan‐treated, and both β‐glucan and spiramycin‐treated groups. Parasitological, histopathological examinations, and immunological analysis were detected. β‐glucan docked complexes demonstrated H‐bonding and hydrophobic interactions towards their promising anti‐toxoplasmosis targets compared to the spiramycin. The treated mice revealed a statistically significant reduction ( p < 0.001) in the parasite burden. Regarding immunocompetent and immunosuppressed division, the group that was treated with both β‐glucan and spiramycin, demonstrated the greatest outcomes, with 71% and 66% efficacy, respectively. It is concluded that β‐glucan shows promising potential as an anti‐toxoplasmosis candidate by potentiating the spiramycin effect and modulating the immunological response.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Zoology Department, Faculty of Science for Girls, Al-Azhar University, Cairo, Egypt.
- Department of Pathology, Theodor Bilharz Research Institute, Giza, Egypt.
- Department of Parasitology, Theodor Bilharz Research Institute, Giza, Egypt.
ORCID-Profile: Eman S El-Wakil
Zitieren
APA
Aboul-Fotouh, A. A., Elfeky, F. A., Omar, N. R., Aboushousha, T., & El-Wakil, E. S. (2025). Investigating Therapeutic Potential of Beta‐Glucan on Experimental Toxoplasmosis in Immunocompetent and Immunocompromised Mice: In Silico and in Vivo Studies. Chemistry & Biodiversity. https://doi.org/10.1002/cbdv.202500370
Vancouver
Aboul-Fotouh AA, Elfeky FA, Omar NR, Aboushousha T, El-Wakil ES. Investigating Therapeutic Potential of Beta‐Glucan on Experimental Toxoplasmosis in Immunocompetent and Immunocompromised Mice: In Silico and in Vivo Studies. Chemistry & Biodiversity. 2025. doi:10.1002/cbdv.202500370
BibTeX
@article{AboulFotouh2025,
author = {Aboul-Fotouh, Asmaa A and Elfeky, Faten A and Omar, Nahed R and Aboushousha, Tarek and El-Wakil, Eman S},
title = {Investigating Therapeutic Potential of Beta‐Glucan on Experimental Toxoplasmosis in Immunocompetent and Immunocompromised Mice: In Silico and in Vivo Studies},
journal = {Chemistry & Biodiversity},
year = {2025},
doi = {10.1002/cbdv.202500370}
}
EUVIMED